Defining Administration Complexity by the Drug, Not the Diagnosis
Biologics in Rheumatology: Revolution & Perspectives
Long-Term Biologic Use May Not Raise Melanoma Risk
Rheumatology Biologic Expertise Valued for COVID-19 Treatment Decisions
No Evidence to Support Biologic Switching Guidelines for JIA
Key Studies Highlighted: 2 Industry Veterans Discuss Their Favorite Annual Meeting Abstracts
FDA Rheumatology Update: New Drug Approvals, Plus Expanded Drug Indications & Safety Concerns
British Columbia Will Be First Canadian Province to Switch Patients to Biosimilars
DMARDs & Biologics Info for Rheumatology Nurses
- 1
- 2
- 3
- …
- 11
- Next Page »